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Maintaining genome integrity requires the accurate
and complete replication of chromosomal DNA.
This is of the utmost importance for embryonic
stem cells (ESCs), which differentiate into cells of
all lineages, including germ cells. However, endoge-
nous and exogenous factors frequently induce stall-
ing of replication forks in every cell cycle, which can
trigger mutations and chromosomal instabilities. We
show here that the oncofetal, nonhistone chromatin
factor HMGA2 equips cells with a highly effective
first-line defense mechanism against endonucleo-
lytic collapse of stalled forks. This fork-stabilizing
function most likely employs scaffold formation at
branched DNA via multiple DNA-binding domains.
Moreover, HMGA2 works independently of other
human factors in two heterologous cell systems to
prevent DNA strand breaks. This fork chaperone
function seemingly evolved to preserve ESC genome
integrity. It is hijacked by tumor (stem) cells to also
guard their genomes against DNA-damaging agents
widely used to treat cancer patients.
INTRODUCTION
The faithful completion of chromosomal DNA replication is a
key cellular process. It prevents mutations and chromosome/
genome instability. This is of particular importance for pluripotent
embryonic stem cells (ESCs), which differentiate into all somatic
cell lineages and germ cells (Cervantes et al., 2002; Petermann
and Helleday, 2010). However, a fraction of replication forks684 Cell Reports 6, 684–697, February 27, 2014 ª2014 The Authorsarrest during each cell cycle when they encounter obstacles
such as DNA lesions or DNA secondary structures in repeat se-
quences present, for example, in telomeres. Replication stalling
often leads to nucleolytic fork collapse (Branzei and Foiani, 2010;
Mirkin and Mirkin, 2007).
Elaborate cell signaling and DNA recombination/repair path-
ways exist in pro- and eukaryotic cells to cope with nucleolytic
lesions at arrested forks (Branzei and Foiani, 2010; Budzowska
and Kanaar, 2009; Paulsen and Cimprich, 2007; Zegerman and
Diffley, 2009). From a cellular perspective, however, the physical
and functional maintenance of stalled forks appears to be a safer
and more economical solution to a seemingly unavoidable prob-
lem. Hence, it is surprising that amore general pathway of repair-
independent fork protection has only recently emerged. Its key
feature is the recognition of single-stranded DNA (ssDNA) re-
gions at stalled or regressed forks.
In Escherichia coli, the RecFOR proteins promote loading of
RecA filaments on ssDNA. Subsequent formation of triple-
stranded RecA complexes on nascent DNA is thought to physi-
cally stabilize forks and prevent strand breakage or degradation
until an obstacle is removed or a second fork comes to the
rescue (Courcelle et al., 2003; Courcelle and Hanawalt, 2003;
Masai et al., 2010). Furthermore, it was shown that RecA alone
can trigger disassembly of replisomes at stalled forks, which
might contribute to fork stability and recovery (Lia et al., 2013).
In mammalian cells, a similar repair-independent protection
mechanism was uncovered more recently. It involves Fanconi
anemia and the tumor-suppressor BRCA1/2 proteins, which sta-
bilize nucleoprotein filaments composed of the mammalian
RecA homolog RAD51 and nascent ssDNA at stalled forks.
This in turn protects DNA strands against degradation by the
MRE11 nuclease and further stabilizes arrested forks until repli-
cation recovery can be achieved (Hashimoto et al., 2010; Lomo-
nosov et al., 2003; Schlacher et al., 2011, 2012). Furthermore, in
eukaryotic cells, replication protein A (RPA) binds to ssDNA at
stalled forks and triggers ataxia telangiectasia RAD3-related
(ATR) ATR-ATRIP checkpoint activation. This in turn results in
checkpoint kinase-1 (CHK1) activation mediated by TOPBP1,
Claspin, and BRCA1 (Aressy and Greenberg, 2012).
Claspin is also an essential component of the so-called fork
protection complex (FPC) made up of the Tim/Tipin and AND1
proteins. The FPC is evolutionarily conserved and is thought
to be part of translocating replisomes where it physically links
helicase and polymerase activities, thereby stabilizing stalled
forks and facilitating successful fork restart (Errico and Cos-
tanzo, 2010, 2012; Tourrie`re and Pasero, 2007). The precise
downstream mechanism(s) that ultimately stabilizes stalled
forks is, however, still elusive and requires phosphorylation of
a number of proteins within a replisome as well as a sufficient
supply of RPA (Bermejo et al., 2011; Branzei and Foiani, 2010;
Cimprich and Cortez, 2008; Toledo et al., 2013). Together, these
repair/recombination-independent fork protection mechanisms,
which usually start at ssDNA regions, reduce the occurrence
of DNA strand breaks and chromosomal aberrations, and pro-
mote cell survival. Given their apparent importance, the exis-
tence of additional mechanisms, especially in stem cells, can
be anticipated.
The mammalian high-mobility group AT-hook 2 (HMGA2)
protein is evolutionarily highly conserved in mammals and is
expressed in ESCs and during early developmental stages.
HMGA2 appears to be absent from normal somatic tissues
(Rogalla et al., 1996), but is reexpressed in most malignant
human neoplasias due to Lin28-mediated let-7 miRNA degrada-
tion (Li et al., 2013). Moreover, the level of expression strongly
correlates with the degree of malignancy and metastatic poten-
tial (Abe et al., 2003; Dro¨ge and Davey, 2008; Fusco and Fedele,
2007; Meyer et al., 2007).
HMGA2 harbors a C-terminal acidic tail and three independent
DNA-binding domains that recognize AT-rich duplex sequences
via the minor groove (Cleynen and Van de Ven, 2008; Huth et al.,
1997; Reeves and Nissen, 1990). In general, HMGA proteins are
considered architectural factors and interact with chromatin in a
highly dynamic manner (Harrer et al., 2004; Reeves and Nissen,
1990). In the context of chromatin, different DNA-binding modes
have been proposed (Pfannkuche et al., 2009). For example, the
three AT-hooks can bind separately to different DNA molecules
in an all trans configuration to create a chromatin scaffold (Vogel
et al., 2011). Interestingly, the HMGA1a protein exhibits higher
binding affinities to Holliday junctions (HJs) than to canonical
AT-rich duplex DNA, and recognizes HJs through multiple con-
tacts at the center of DNA branch points (Hill et al., 1999; Hill
and Reeves, 1997). Furthermore, a wheat HMGA homolog also
binds to HJs with high affinity (Zhang et al., 2003).
In addition to the known involvement of HMGA2 in the regula-
tion of gene expression and cell transformation/differentiation
processes (Cleynen and Van de Ven, 2008; Fedele et al., 2010;
Pfannkuche et al., 2009), we recently provided evidence for a
role of HMGA2 (and HMGA1) in the protection of HMGA-positive
cancer cells against DNA-damage-induced cytotoxicity (Sum-
mer et al., 2009). We attributed this protective effect to a dRP/
AP lyase activity of HMGA2 and a link to base excision repair.
Strikingly, however, the strongest protective effect was detectedCagainst hydroxyurea-induced cell death, hinting at a possible
additional role of HMGA2 at stalled forks.
In this study, we find that HMGA2 is a bona fide replication fork
chaperone in ESCs and cancer cells that substantially stabilizes
physical fork integrity. Strikingly, in E. coli, human HMGA2
alone is sufficient to both fully complement the RecA protein
in its known replication fork-stabilizing role and suppress
antimicrobial peptide-induced cleavage specifically at branched
DNA structures in vivo. In Saccharomyces cerevisiae, HMGA2
partially complements the fork-stabilizing function of ATR/
Mec1 by reducing the occurrence of collapsed, regressed forks
and their subsequent endonucleolytic collapse. We have thus
uncovered an important repair/recombination-independent
replication fork protection pathway that is unique to stem and
cancer cells that express HMGA2.
RESULTS
HMGA2 Stably Associates with Sites of DNA Replication
Detection of endogenous HMGA2 in human fibrosarcoma
HT1080 cells by immunostaining revealed the expected colocal-
ization with DAPI-stained DNA inside the cell nucleus (Fig-
ure S1A, top panels). We noted, however, the existence of
numerous diffuse HMGA2 foci and hypothesized that they repre-
sent a distinct, more stably associated chromatin fraction of
HMGA2. Next, a staining protocol allowed us to substantially
reduce the weaker chromatin-associated HMGA2 fraction and
to observe clear, individual HMGA2 foci (Figure S1A, bottom
panels).
We pulse-labeled DNA in human fibrosarcoma HT1080 and
mouse ESCs (mESCs) with 5-iodo-20deoxyuridine (IdU) and
detected more than 80% colocalization of IdU with HMGA2 sig-
nals. This was the case in both the absence and presence of
hydroxyurea (HU) (Figures 1A and 1E). HU causes arrest of repli-
cation forks through the inhibition of ribonucleoside diphosphate
reductase (Krakoff et al., 1968). This result suggested that a
fraction of HMGA2 molecules are stably associated with both
ongoing and stalled replication sites.
We next determined whether HMGA2 colocalized with RPA
and/or proliferating cell nuclear antigen (PCNA) before and after
HU treatment. RPAandPCNAare bound at ongoing and arrested
forks (Fanning et al., 2006; Sirbu et al., 2011). The vast majority of
cells exhibited costaining for HMGA2/RPA and HMGA2/PCNA,
and quantification per cell revealed that more than 80% of RPA
signals and up to 90% of PCNA signals colocalized with distinct
HMGA2 foci irrespective of HU treatment (Figures 1Band 1F, and
1C and 1G, respectively). Similar results were obtainedwith a dif-
ferent primary HMGA2 antibody for RPA costaining (Figure S1B).
As expected, quantification of immunostaining betweenRPAand
PCNA also revealed substantial (>90%) colocalization before
and after HU treatment (Figures 1D and 1H).
To provide further evidence that HMGA2 is localized at replica-
tion sites containing ongoing and/or stalled replication forks, we
performed proximity ligation assays (PLAs), which are a sensitive
measure that can detect in situ whether two proteins are colocal-
ized and not more than 40 nm apart (So¨derberg et al., 2006). We
counted PLA foci in at least 55 cell nuclei per sample, and the
data revealed colocalization for HMGA2 and RPA, HMGA2 andell Reports 6, 684–697, February 27, 2014 ª2014 The Authors 685
Figure 1. HMGA2 Associates with Replication Sites Containing Ongoing and Stalled Forks
(A) Human HT1080 fibrosarcoma cells and mESCs were pulse labeled for 25 min with IdU and treated for 24 hr with HU (+HU) followed by immunostaining with
antibodies recognizing HMGA2 (green) and IdU (red). Untreated (HU) cells were processed for immunostaining immediately after IdU labeling. Genomic DNA
was visualized by DAPI staining.
(B) Replication foci associated with HMGA2 were identified by coimmunostaining for RPA and HMGA2. See also Figure S1B.
(C) Coimmunostaining between HMGA2 and PCNA.
(D) Coimmunostaining between PCNA and RPA32.
(E–H) Quantification of colocalizing signals per cell as depicted in (A)–(D), respectively. For each sample, 20 cells were analyzed using LSM710 ZEN software and
the mean percentage value + SD was determined. Two independent experiments were quantified, yielding very similar results. We show the results of one
experiment.PCNA, and, as a control, RPA and PCNA, irrespective of the
presence or absence of HU (Figures 2A and 2B). Furthermore,
the data revealed that PLA foci were significantly enriched in
cells engaged in DNA replication, as evidenced by incorporation686 Cell Reports 6, 684–697, February 27, 2014 ª2014 The Authorsof 5-ethynyl-20-deoxyuridine (EdU; Figure 2B, EdU and EdU+).
Controls employing only one of the four primary antibodies
showed significantly reduced numbers of PLA foci per cell (Fig-
ures 2A–2C).
Figure 2. HMGA2 Is in Close Proximity to Replication Factors RPA32 and PCNA
(A) Human HT1080 fibrosarcoma cells were labeled for 15minwith EdU and treated with hydroxyurea (+HU) for 16 hr in the continued presence of EdU. Untreated
(HU) cells were processed for PLAs immediately after 15 min of pulse labeling. Genomic DNA was visualized by DAPI staining. The presence of primary
antibodies used for PLA and controls is indicated at the left side of the panels.
(B and C) Quantification of PLA foci. For each sample, PLA foci in at least 55 cells (EdU(+) plus EdU()) were counted and the mean values were determined. We
show mean values, SDs, and statistically significant differences from two independent experiments for each sample (**p < 0.01).
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We also performed chromatin immunoprecipitation experi-
ments on small chromatin fragments (0.2–2 kb) using antibodies
against bromodeoxyuridine (BrdU)-labeled nascent DNA to
further demonstrate that HMGA2 is associated with replicating
DNA. The ratio of HMGA2 to histone H3 was quantified in the
input chromatin and the pulled-down fraction. The data revealed
a 10- and 4-fold enrichment of HMGA2 at sites of ongoing repli-
cation in HT1080 and mESCs, respectively. Moreover, HMGA2
remained enriched (18- to 3-fold) at BrdU-labeled sites during
HU treatment in both cell types (Figures S1C–S1F).
Taken together, these results indicated that HMGA2 is stably
associated with replication foci containing ongoing and stalled
replication forks. Furthermore, specifically in cells engaged in
DNA replication, HMGA2 must be in close proximity to two key
replication factors.
HMGA2 Protects against Nucleolytic Fork Collapse
In order to investigate whether the association of HMGA2 with
replication sites or factories influences stalled fork stability, we
first employed two recombinant fibrosarcoma cell lines,
HT1080-C1 and HT1080-C2, which enabled us to substantially
knock down endogenous HMGA2 levels via doxycycline-induc-
ible expression of small hairpin RNA (shRNA) complementary to
a sequence present in the 30-untranslated region of HMGA2
mRNA (Figure 3A). As a control, parental HT1080 cells were first
treated for 24 hr with increasing amounts of HU, and pulsed-field
gel electrophoresis (PFGE) revealed that the fraction of shorter
genomic DNA fragments (24–450 kb) increased with a concom-
itant decrease of larger fragments (450–2,200 kb) (Figure 3B).
This shift in DNA fragmentation pattern is consistent with an
overall increase in endonucleolytic fork collapse at elevated
HU concentrations (Petermann et al., 2010).
HMGA2 knockdown (KD) in conjunction with HU treatment
showed that HMGA2 suppressed fork collapse at low and high
HU concentrations, as indicated by comparatively smaller
amounts of shorter and larger amounts of longer genomic frag-
ments when HMGA2 levels remained unperturbed (Figure 3C,
left and middle panels). Control experiments with parental cells
showed that this suppression was due to HMGA2 KD via shRNA
expression (Figure 3C, right panels). Furthermore, no significant
differences in apoptosis/necrosis or impact on cell cycle could
be detected between HMGA2-expressing and KD cells after
HU treatment (Figures S2A and S2B, and S2C and S2D, respec-
tively). Neutral comet assays performed on HT1080 and
HT1080-C1 cells corroborated our results obtained with PFGE
(Figures S2E–S2I).
The specificity of shRNA-mediated HMGA2 KD was revealed
in rescue experiments with expression vectors for HMGA2 trans-
fected into HT1080-C1 cells after doxycycline-induced KD of the
endogenous protein (Figures S3A and S3B). PFGE of genomic
DNA isolated after 24 hr HU treatment and quantification of
DNA fragments arising from double strand breaks (DSBs) in
four independent experiments revealed that compared with con-
trol transfections, expression of exogenous HMGA2 significantly
reduced fork collapse to a level comparable to that seen in the
presence of endogenous HMGA2, i.e., in HU-treated cells in
the absence of doxycycline (Figures S3C and S3D). HMGA2
KD in HT1080-C1 cells also confirmed the specificity of688 Cell Reports 6, 684–697, February 27, 2014 ª2014 The AuthorsHMGA2 antibodies used in the colocalization and PLA studies
shown in Figures 1 and 2 (also see Figures S3F and S3G, and
S3H, respectively).
We next performed comet assays on pluripotent human ESCs
after exposure to the DNA methylating agent methyl methane-
sulphonate (MMS), which also triggers fork arrest (Tercero and
Diffley, 2001). We employed small interfering RNA (siRNA)-medi-
ated HMGA2 KD and confirmed a general protective function
exerted by endogenous HMGA2 against fork cleavage, as indi-
cated by a significant increase in the amount of fragmented
DNA seen in the comet tails when endogenous HMGA2 levels
were reduced by about 50% (Figure 3D). Together, these results
are in excellent agreement with previous findings that revealed
significant protective effects of HMGA2 against drug-induced
DNA damage in mouse embryonic fibroblasts and in human can-
cer cells expressing exogenous HMGA2 (Palmieri et al., 2011;
Summer et al., 2009).
A general protective function of HMGA2 against nucleolytic
fork collapse leading to DSBs was further substantiated by our
finding that KD of endogenous HMGA2 in HT1080-C1/C2 cells
led to a marked increase in the amount of the phosphorylated
form of ataxia telangiectasia mutated (ATM-pSer1891) protein
due to HU treatment (Figure 3E). We also found that HMGA2
does not affect the basal expression levels of ATM or ATR. In
addition, the presence of HMGA2 showed no influence on
ATR-mediated phosphorylation of CHK-1 (CHK1-pSer345) (Fig-
ure 3E), which serves as a cell signal indicating the presence of
stalled replication forks (Cimprich and Cortez, 2008). The latter
result also indicates that KD of endogenous HMGA2 does not
impact the cell cycle during the period of HU treatment.
We next showed that both the intensity and number of foci
formed by histone variant g-H2AX at sites of either spontaneous
or induced DNA breakage (Kinner et al., 2008) were significantly
reduced in HMGA2-expressing human thyroid UTC8505 cancer
cells before or immediately after MMS treatment (Figure S3I and
S3J). Together, these results indicated that endogenous HMGA2
efficiently protects stalled forks against nucleolytic collapse in a
variety of human cell types.
HMGA2 Protects Nascent DNA Strands and Promotes
Replication Recovery
We next investigated whether HMGA2 protects the integrity of
nascent DNA at arrested forks, using DNA fiber analyses. We
found no significant effect on fiber length due to HMGA2 KD in
untreated HT1080-C1/C2 cells. However, after exposure to HU
for 24 hr, the length of prelabeled nascent DNA in HMGA2 KD
cells was substantially reduced compared with that of cells
with unperturbed HMGA2 levels (Figures 4A–4C). Control exper-
iments using parental HT1080 cells confirmed that the instability
of nascent DNA strands was due to HMGA2 KD via shRNA
expression (Figure 4D).
In order to test whether the observed protective effect on
nascent DNA strands in HMGA2-positive cells affects the restart
of DNA synthesis upon release of the HU block, we performed
BrdU incorporation assays. By determining the incorporation
ratios in HMGA2-positive (i.e., doxycycline-untreated) and
HMGA2 KD (i.e., doxycycline-treated) HT1080-C1/C2 cells
during the 8 hr recovery after HU treatment, we observed that
Figure 3. HMGA2 Protects Arrested Replication Forks from Collapsing into DSBs
(A) Western blot showing the downregulation of endogenous HMGA2 levels via doxycycline (DOX), which triggers HMGA2 shRNA expression and HMGA2 KD in
two recombinant HT1080 cell lines. The parental cell line lacking the shRNA construct is shown as control.
(B) PFGE of genomic HT1080 DNA after treatment with increasing amounts of HU, as indicated. Intensity scans revealed a shift from larger to smaller fragments.
(C) Lack of HMGA2 led to the accumulation of smaller genomic fragments after HU treatment, indicating that more stalled forks collapsed as a result of
endonucleolytic cleavage. Experiments were done in triplicate and one representative experiment is shown, with parental HT1080 cells as control. See also
Figure S2.
(D) Comet assay performed on human ESCs (HUES7) after siRNA-mediated HMGA2 KD (western) and exposure to MMS without recovery. Nonspecific siRNA
(siNT) was used as control. Experiments were done in triplicate. We show one representative example with 100 comets analyzed for each sample. Statistically
significant differences in Olive moments are marked (*p < 0.05, **p < 0.01).
(E) Western blot analysis of ATM, phosphorylated ATM, ATR, HMGA2, and phosphorylated CHK1 using b-actin as the normalizing control before and after HU
treatment, as indicated. The data presented here were obtained with HT1080-C1 cells. HT1080-C2 cells yielded very similar results. We showmean values of the
respective protein ratios, SDs, and statistically significant differences from three independent experiments (*p < 0.05, **p < 0.01).
See also Figure S3.the presence of HMGA2 ensured much shorter recovery times
(Figure 4E). Taken together, these results indicated that
HMGA2 does not affect nascent DNA integrity at normal ongoing
replication forks, but helps to preserve these strands at stalled
forks.CThe shorter DNA synthesis recovery times in the presence of
HMGA2 led us to investigate whether this coincided with
changes in the amount of chromatin-bound replisome compo-
nents. To that end, we performed quantitative analyses of total
chromatin-associated PCNA and RPA (Go¨risch et al., 2008;ell Reports 6, 684–697, February 27, 2014 ª2014 The Authors 689
Figure 4. HMGA2 Preserves Nascent DNA Strand Integrity after HU
Treatment and Promotes Genome Stability
(A–D) DNA fiber analyses after IdU pulse labeling and subsequent HU treat-
ment. The principal experimental outline is diagrammed and representative
examples of fibers under different experimental conditions are shown in (A).
Mean values for replication tract length frequencies under various experi-
mental conditions, as indicated, were determined for HT1080-C1 (B), HT1080-
690 Cell Reports 6, 684–697, February 27, 2014 ª2014 The AuthorsYu et al., 2012). The data revealed that the amount of RPA and
hyperphosphorylated RPA increased during HU treatment due
to the uncoupling of DNA synthesis from unwinding at stalled
forks, and that this increase was unaffected by HMGA2 KD (Fig-
ure S4). Furthermore, it is known that phosphorylation of RPA is
cell-cycle dependent, and the lack of obvious phosphorylation
pattern differences therefore corroborates our earlier data
showing that KD of HMGA2 does not impact the cell cycle during
HU treatment. We also showed that the amount of PCNA re-
mained at comparable levels during HU treatment irrespective
of HMGA2 KD (Figure S4). Interestingly, the amount of chro-
matin-bound HMGA2 increased substantially during HU treat-
ment (Figure S4) and coincided with the onset of detectable
genomic DNA fragmentation due to HU treatment (data not
shown). We infer that HMGA2 at a global chromatin level neither
interferes with the stability of a key replisome component, as
indicated by similar amounts of chromatin-bound PCNA without
HMGA2 KD, nor affects uncoupling of DNA synthesis from
unwinding at arrested forks, as indicated by the comparable
amounts of chromatin-bound RPA.
HMGA2 Promotes Genome Stability and Cell Survival
after Replication Stress
The observed enhanced physical integrity of stalled forks medi-
ated by HMGA2 could lead to a reduction in chromosomal
aberrations (Schlacher et al., 2011, 2012). In order to test this
possibility, we analyzed chromosome spreads at 24 or 48 hr
after recovery from HU treatment. Strikingly, the results re-
vealed that KD of HMGA2 significantly increased the percent-
age of metaphase spreads with aberrations (Figures 4F and
4G). In addition, the average number of HU-induced aberrations
per metaphase spread increased in C1 and C2 cells when
HMGA2 levels were reduced (Figure 4H). A closer inspection
of the localization of small chromosomal deletions in cells
with reduced HMGA2 levels revealed that more than 80%
occurred on only one of the two sister chromatids, indicating
that they were derived from replication problems (data not
shown).C2 (C), and parental HT1080 cells (D). Mean values and SDs are from three
independent experiments.
(E) Replication forks recovered faster in the presence of HMGA2, as indicated
by an increased ratio of BrdU incorporation in unperturbed C1 and C2 cells
compared with KD conditions. No substantial differences due to doxycycline
treatment were found for parental HT1080 cells. Mean values and SDs are from
three independent experiments.
(F–H) HMGA2 promotes chromosomal stability after drug treatment. The
experimental outline is diagrammed in (F). We show representative examples
of different types (black arrowhead indicates gaps or breaks, red arrowhead
indicates dicentric, blue arrowhead indicates radials) of chromosomal in-
stabilities found to be increased due to lack of HMGA2. Experiments were
performed twice. We show one as a representative example, including
parental cells as control. For each sample, images of 40–60 spreads were
taken and analyzed.
(I) MTT assays revealed that HMGA2 increased cell viability after HU treatment.
Mean values of the respective ratios (DOX/DOX+), SDs, and statistically
significant differences in cell survival between cells with unperturbed and KD
HMGA2 levels from three independent experiments are indicated (*p < 0.05,
**p < 0.01).
See also Figure S4.
Figure 5. HMGA2 Preferentially Binds and Stabilizes Three- and
Four-Way DNA Structures In Vitro
(A) EMSAs reveal higher affinities of HMGA2 for YSs and HJs compared with
canonical duplex DNA in the presence of excess competitor DNA (salmon
sperm DNA).
(B and C) HMGA2 binding protects HJs (B) and YSs (C) from temperature-
induced duplex melting even at low protein:DNA stoichiometries.
See also Table S1.Another potential consequence of HMGA2-mediated stalled
fork protection is enhanced cell survival. We demonstrate that
particularly at elevated HU concentrations, HMGA2 significantly
promoted cell survival over a period of several days during re-
covery (Figure 4I). This is consistent with our previous data
obtained with HMGA2-overexpressing A459 and HeLa cells
(Summer et al., 2009), and with results from other studies (Natar-
ajan et al., 2013; Palmieri et al., 2011). Furthermore, the rescueCexperiments described above also confirmed that the survival-
promoting effect after HU challenge is specific for HMGA2
(Figure S3E).
HMGA2 Chaperones Three- and Four-Way DNA
Junctions
To probe further into the role of HMGA2 in replication fork integ-
rity at the molecular level, we studied interactions between
HMGA2 and two branched DNA structures that are thought to
be present at stalled forks (Branzei and Foiani, 2010; Petermann
and Helleday, 2010; Ray Chaudhuri et al., 2012). We performed
electrophoretic mobility shift assays (EMSAs) using in vitro
assembled Y structures (YSs) and HJs. The results showed
that in the presence of excess genomic competitor DNA,
HMGA2 exhibited about 10-fold higher affinities for both
branched DNAs in comparison with canonical AT-rich duplex
DNA (Figure 5A; compare lanes with 1 mg competitor). Notably,
this result is in agreement with previous reports that revealed a
substantially higher affinity of the closely related HMGA1a pro-
tein for HJs (Hill et al., 1999; Hill and Reeves, 1997).
In order to test whether binding of HMGA2 enhanced the phys-
ical stability of YSs and HJs, we preincubated increasing
amounts of HMGA2 with fixed amounts of DNA substrates and
subsequently shifted the complexes to elevated temperatures.
EMSAs revealed substantial protection for both branched DNA
structures against DNA melting at HMGA2:DNA stoichiometries
as low as 2:1 (Figures 5B and 5C).
HMGA2 Complements RecA in E. coli after Replication
Stress
HMGA2 is a multifunctional protein in human cells. Its known
pleiotropic effects are mediated by binding to chromatin via
AT-hook domains and may involve protein-protein interactions
via the C-terminal domain (Cleynen and Van de Ven, 2008; Fusco
and Fedele, 2007; Pfannkuche et al., 2009). To provide further
evidence for our hypothesis that HMGA2 is directly and solely
responsible for the protection of stalled replication forks in vivo
in the absence of other human factors, we chose heterologous
E. coli as a model system in which the RecA protein primarily ful-
fills such a protective role (Courcelle and Hanawalt, 2003; Masai
et al., 2010). We employed E. coli recA knockout (DrecA) and
corresponding wild-type (WT) cells in conjunction with inducible,
low-level expression of human HMGA2 (Figure S5A). Impor-
tantly, LexA-dependent reporter systems ensured that the
expression of HMGA2 did not per se lead to activation of the
E. coli SOS response in DrecA cells (data not shown).
We exposed E. coli cells to either HU or low pH (the latter treat-
ment induces abasic DNA lesions, which in turn also trigger repli-
cation fork stalling; Maga et al., 2009). Colony-formation assays
revealed that human HMGA2 fully restored DrecA cell viability to
WT levels after exposure to HU, but showed no significant effect
on WT cells (Figure 6A). Strikingly, HMGA2 also strongly pro-
tected against pH-induced cell death up to a level exceeding
even WT cell viability (Figure 6B).
It has been shown that about 10% of DrecA cells are filamen-
tous. Several lines of evidence indicate that this phenotype is
due to a failure in chromosome segregation, which is caused
by a lack of protection of stalled forks near so-called terminationell Reports 6, 684–697, February 27, 2014 ª2014 The Authors 691
Figure 6. In Vivo RecA Complementation and Hexamer-Induced
DNA Cleavage Assays
(A and B) Cell viability of WT and DrecA cells. (+) and (–) human HMGA2
expression, as indicated, was determined by colony-forming units (cfu) after
exposure to either HU (A) or low pH (B). Mean cfu values, SDs, and statistically
significant differences from three independent experiments are indicated
(**p < 0.01). See also Figure S5A.
(C) DAPI staining of WT and DrecA cells, with and without HMGA2 expression,
as indicated.
(D) Quantitation of comet assays performed either immediately after HU
treatment or during a recovery period revealed significant protection against
DSBs in the presence of RecA or HMGA2. SDs from three independent
experiments and statistically significant differences are indicated (*p < 0.05,
**p < 0.01). See also Figure S5B.
(E and F) HMGA2 expression promotes growth recovery after HU treatment in
DrecA cells (E) and low pH treatment in WT and DrecA cells (F).
(G) Comet assays revealed a significant protection by HMGA2 against DSBs
induced by the peptide wrwycr at branched DNA. Controls either lacked
peptide or included DMSO as solvent. SDs from three independent experi-
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presence of HMGA2 completely eliminated filamentous cell
growth in DrecA cells (Figure 6C).
Impaired protection of arrested forks should also lead to an
increase in DSBs in DrecA cells. We performed neutral comet
assays and found that HMGA2, similarly to RecA in WT cells,
significantly reduced the extent of HU-induced fork breakage,
even after a recovery period (Figures 6D and S5B). This effect
mirrors the protective function against nucleolytic lesions
described above for HMGA2 in human cells.
In order to test whether fork protection mediated by HMGA2
results in faster fork recovery, as observed with human cells,
we transferred WT and DrecA cells to new medium after 2 hr of
HU treatment. Whereas HMGA2 expression had no effect on
the growth of WT cells, DrecA cells recovered from replication
arrest about 2 hr faster when HMGA2 was present (Figure 6E).
Significant recovery improvements were also observed following
low pH treatment, in particular for DrecA cells (Figure 6F).
HMGA2 Interferes with Peptide-Induced Cleavage of
Branched DNA
Previous studies showed that the peptide hexamer wrwycr spe-
cifically binds to and blocks processing of YSs and HJs in bac-
terial cells (Gunderson and Segall, 2006; Kepple et al., 2008).
This in turn leads to potent antimicrobial effects that are direct
consequences of endonucleolytic attacks at these blocked, in-
termediate DNA structures, most likely at stalled forks.
We utilized the hexamer in combination with comet assays to
test whether the presence of HMGA2 affects the extent of pep-
tide-induced DNA cleavage in DrecA cells. The results revealed
significantly fewer DSBs when HMGA2 was present (Figures 6G
and S5C). Furthermore, EMSAs demonstrated strong binding
competition between hexamer and HMGA2 on YSs (Figure 6H).
Taken together, these results indicate that human HMGA2 alone
is able to protect against DNA damage at stalled forks in E. coli
via direct physical interactions with branched DNA.
Protection of Arrested Forks Requires Three Functional
AT-hooks in cis
In order to provide further evidence for a direct association be-
tween HMGA2 and DNA at stalled forks as a prerequisite for its
fork-stabilizing function, we inactivated individual AT-hooks via
substitution of two critical residues per hook motif. Strikingly,
HMGA2 variants carrying substitutions either in AT-hook 2 alone
or in both AT-hooks 2 and 3 completely failed to complement
RecA, while inactivation of AT-hook 3 alone led to a substantial
(4-fold) loss of protective power against HU-mediated cellments and statistically significant differences are indicated (*p < 0.05). See also
Figure S5C.
(H) EMSAs performed after incubation of a fixed amount of HMGA2with YSs at
a 5:1 stoichiometry in the presence of increasing amounts of peptide revealed
strong DNA binding competition.
(I and J) DrecA cells were transformed with various HMGA2 mutants carrying
nonfunctional AT-hook(s) (I) or HMGA1a (J), and cell survival was determined
by colony formation (cfu) before and after 2 hr of HU treatment with or without
human protein induction as indicated. Mean values of cfu, SDs, and statisti-
cally significant differences from three independent experiments are indicated
(**p < 0.01). See also Figures S5D–S5G.
death compared with the parental protein (Figure 6I and S5D). In
agreement with this finding, the suppression of filamentous cell
growth of the DrecA strain by HMGA2 is also AT-hook depen-
dent (Figure S5E). Hence, the presence of all three AT-hooks
appears to be essential for an efficient replication fork-stabilizing
function of HMGA2. Notably, previous results revealed that
stable binding of HMGA1a to HJs in vitro also required the pres-
ence of three functional AT-hooks per HMGA1a molecule in cis
(Hill et al., 1999).
We next confirmed these findings using human HT1080 cells
and transient transfection assays with vectors for WT HMGA2
or AT-hook variants, followed by 24 hr of HU treatment and re-
covery. We first confirmed similar expression levels of recombi-
nant HMGA2 (data not shown), and cell-survival assays revealed
that expression of WT HMGA2, in addition to the endogenous
protein, significantly increased cell viability compared with
mock-transfected cells (Figure S5F). Complete loss of this pro-
tective effect was observed at 100 mMHU with HMGA2 variants
harboring either an inactivated AT-hook 2 or inactivated AT-
hooks 2 and 3 (Figure S5F). We were also able to confirm that
three functional hooks are required to suppress fork collapse
and promote cell survival in rescue experiments comparing
expression vectors for WT and the HMGA2 variant harboring
mutated hooks 2 and 3 (Figure S3E).
HMGA1a Complements RecA after Replication Stress
The AT-hook DNA-binding domains are highly conserved in the
human HMGA1 and HMGA2 proteins. HMGA1, like HMGA2, is
primarily expressed in pluripotent stem cells and most primary
human cancer cells (Fusco and Fedele, 2007). Hence, we next
determined whether the fork-stabilizing function of HMGA2 is
conserved in the HMGA protein family. Specifically, we tested
whether expression of the human HMGA1a variant in E. coli
DrecA cells leads to increased viability after HU treatment. The
results showed that fork protection appears to be an intrinsic
and conserved function of human oncofetal HMGA proteins (Fig-
ures 6J and S5G).
HMGA2 Stabilizes Stalled Replication Forks in
S. cerevisiae
In order to probe further into the mechanism of the proposed
function of HMGA2 as an independent replication fork chap-
erone, we employed S. cerevisiae as a heterologous eukaryotic
cell system that lacks HMGA orthologs. In yeast, the Mec1
protein (an ATR ortholog) has a crucial fork-stabilizing activity
(Tercero et al., 2003). We therefore employed a mec1Dsml1D
double-mutant strain carrying a galactose-inducible GAL-
HMGA2 gene construct stably integrated at the TRP1 locus
(Figure 7A) to test the extent to which human HMGA2 can com-
plement this fork-stabilizing function during induced replication
stress.
We first confirmed that the expression of human HMGA2 had
no influence on the progression of the cell cycle in both WT and
mec1 Dsml1D cells (data not shown). Mec1-deficient yeast cells
are known to lose viability rapidly when treated with HU. We
found that the expression of HMGA2 noticeably increased the
viability of mec1D sml1D cells that were preexposed to HU
(Figure 7B).CThe mec1D sml1D cells then allowed us to directly probe into
the structure of a synchronized, early-firing replicon on chromo-
some III (ARS305) after HU challenge in the presence or absence
of HMGA2 (Lopes et al., 2001). The results of two-dimensional
gel electrophoresis followed by Southern blotting revealed the
presence of a so-called X-spike, which indicates regressed,
chicken-foot-like fork structures in mec1D sml1D cells, but not
in WT or mec1D sml1D-expressing HMGA2 cells, implying
that HMGA2 partially protected stalled replication forks from
collapsing into a X-spike (Figure 7C; Hu et al., 2012; Lopes
et al., 2001). The fact that ‘‘late Y-forks’’ were seen for a longer
period in mec1D sml1D cells expressing HMGA2 compared
withmec1D sml1D cells is consistent with this notion (Figure 7C).
Since it is known that collapsed replication forks are prone to
subsequent endonucleolytic attack leading to DSBs (Lopes
et al., 2001; Petermann et al., 2010), we employed PFGE and
observed a reduction of DNA fragmentation globally and on
chromosome III in HU-treated mec1D sml1D cells when human
HMGA2 was expressed (Figure 7D, top and bottom panels,
respectively). Hence, the observed increase in viability of
HMGA2-positivemec1D sml1D cells coincideswith a substantial
protection against endonucleolytic cleavage of DNA, which in
turn appears to be due, at least in part, to the prevention of
fork regression/collapse.
DISCUSSION
A fraction of replication forks always encounter obstacles during
translocation along the parental DNA, and physical stabilization
of arrested forks represents a first line of defense against fork
collapse (Branzei and Foiani, 2010;Mirkin andMirkin, 2007). Sta-
bilization can be achieved by the fork protection complex or is
generally initiated by recognition of ssDNA (Branzei and Foiani,
2010; Courcelle et al., 2003; Errico and Costanzo, 2010, 2012;
Schlacher et al., 2011, 2012). We show in this study that
HMGA2 specifically equips ESCs and cancer cells with an addi-
tional fork protection mechanism, which differs from other path-
ways (Atkinson and McGlynn, 2009; Courcelle and Hanawalt,
2003; Petermann and Helleday, 2010; Schlacher et al., 2011,
2012).
Our results revealed stable association of HMGA2 with human
replication foci containing either ongoing or arrested forks. It has
been described that the highly homologous HMGA1a protein in-
teracts with subunits of the human origin recognition complex
(ORC) via its C-terminal domain (Thomae et al., 2008, 2011).
Given the high degree of conservation, it is possible that
HMGA2 also interacts with ORC and remains there after initiation
of replication has occurred (Natsume and Tanaka, 2010).
We have shown that the presence of HMGA2 does not impact
ongoing replication. In addition, the lack of HMGA genes does
not alter cell growth, indicating that HMGA proteins are not
essential factors for DNA replication (Beitzel and Bushman,
2003; Palmieri et al., 2011). However, when forks are arrested,
the presence of HMGA2 protects forks from nucleolytic collapse.
Our biochemical data revealed that HMGA2 binds with high
affinity to branched DNA. Current models favor two types of
branched structures forming at stalled forks (Branzei and Foiani,
2010): the three-way junction, which resembles an unperturbedell Reports 6, 684–697, February 27, 2014 ª2014 The Authors 693
Figure 7. HMGA2Stabilizes Stalled Replica-
tion Forks in S. cerevisiae
(A) Western blot showing expression of HMGA2-
(HA)9 after 2 hr galactose induction in WT, Dmec1,
and Dmec1+HMGA2 strains.
(B) Cell viability was determined as cfu after
exposure to 30 mg/ml HU for the times indicated.
Mean values of cfu, SDs, and statistically signifi-
cant differences from three independent experi-
ments are indicated (**p < 0.01).
(C) Replication intermediates arising from the
ARS305 origin in response to HU were studied by
two-dimensional gel electrophoresis. The position
of the X-spike signal that contains reversed,
chicken-foot-like forks is indicated by black
arrows. Experiments were done in duplicate and
one representative experiment is shown.
(D) PFGE analysis of the occurrence of DSBs in the
yeast genome, as revealed by ethidium bromide
staining (top), and in chromosome III (probe:
ARS305; bottom) during HU treatment.
(E) Model of HMGA2-mediated protection of
stalled replication forks. See text for details.YS, and the HJ or chicken-foot structure that results from fork
reversal. Here, we propose that HMGA2 forms a protective scaf-
fold with branched DNA at arrested forks. This interaction might
be favored in human cells by a high local concentration of
HMGA2 inside replication foci, perhaps through interactions
with ORC or replisome components, such as Ku70/80 (Sgarra
et al., 2008). The proposed HMGA2 scaffold physically stabilizes
stalled fork structures, seemingly without interfering with PCNA
association or RPA loading, thereby promoting genome integrity
and cell survival.
In this context, it is possible that the presence of HMGA2 at
stalled replication forks engages its recently discovered dRP/
AP lyase activity to more efficiently initiate base excision repair
at abasic sites (Summer et al., 2009). The increased cell viability
in the presence of HMGA2 observed in the heterologous E. coli
system after low pH challenge already points to such a possibil-694 Cell Reports 6, 684–697, February 27, 2014 ª2014 The Authorsity. Further studies are needed to shed
more light on this emerging HMGA2-
mediated connection between fork sta-
bility and DNA repair.
Our model suggests that HMGA2 can
work independently of other human fac-
tors in stabilizing stalled forks. This is
based on results obtained with two heter-
ologous cell systems. In E. coli, comple-
mentation of RecA led to a reduction in
DNA strand breaks, the elimination of fila-
mentous growth, and an increase in cell
survival and recovery times after replica-
tion stress. Furthermore, the E. coli sys-
tem provided evidence that HMGA2
works directly at the level of replication
forks. First, by employing the hexapep-
tide wrwycr, which specifically binds to
branched DNA structures in vivo and trig-gers DNA strand breaks at stalled forks and HJs (Gunderson and
Segall, 2006), we demonstrated that HMGA2 suppresses pep-
tide-induced DNA lesions most likely via binding competition.
Second, variants of HMGA2 carrying inactivated AT-hook
domains failed to complement RecA, hence revealing a require-
ment for the presence of all three AT-hooks for fork protection.
This scenario is supported by the finding that stable binding of
HMGA1a to HJs also requires the presence of three functional
AT-hooks (Hill et al., 1999).
The yeast system allowed us to demonstrate that the fork-
stabilizing function of HMGA2 reduced, to a discernible extent,
the number of pathological forks. This contributed to an overall
reduction in genome fragmentation and an increase in cell
viability after HU-induced replication stress. The yeast Mec1/
ATR knockout system in conjunction with western blotting of hu-
man ATR/pCHK1 proteins also indicated that HMGA2 functions
independently of the fork-based ATR-pCHK1 signaling pathway.
Notably, the dynamics of phosphorylation at serine 345 of CHK1
were not affected by HMGA2 protein levels. This is in agreement
with recent data that hinted at a CHK1-independent function of
HMGA2 in preventing apoptosis as a result of replication stress
(Natarajan et al., 2013).
The cellular consequences of replication stress depend on the
extent of the DNA damage inflicted and the genetic background.
We exposed cells to high HU concentrations for 24 hr, which led
to a significant increase in chromosomal aberrations and a
decrease in cell viability. The fact that HMGA2 efficiently protects
stalled forks under these conditions implies that the proposed
interaction must be quite stable—a scenario that is strongly sup-
ported by our biochemical data. Although HMGA2 seemingly
acts on its own when all three AT-hooks are functional, contrib-
uting protein-protein interactions betweenHMGA2 and other hu-
man factors (e.g., Ku70/80) are not ruled out (Sgarra et al., 2008).
Our data show that arrested fork stabilization by HMGA2 leads
to significantly shorter replication recovery times. The fact that
HMGA2 protects nascent DNA strands might indicate that
stalled forks are maintained in a functional, replisome-bound
state. However, our combined data indicate that it is more likely
that forks are rescued by the firing of dormant replication origins
located within the same replicon (Blow et al., 2011; Ge and Blow,
2010; Kawabata et al., 2011) or perhaps through recruitment of
PrimPol (Mouro´n et al., 2013).
HMGA proteins are primarily expressed in pluripotent stem
cells and in most human malignancies (Cleynen and Van de
Ven, 2008; Fedele and Fusco, 2010; Fedele et al., 2010). These
cells are highly metabolically active and exhibit fast DNA replica-
tion cycles. Therefore, it is conceivable that stalling of replication
forks occurs quite frequently in these cell types. We employed a
variety of ESC and cancer cell lines to demonstrate that HMGA2
has a potent general fork chaperone function. For ESCs, this pro-
tection pathway may be an important component of a genome
surveillance system to prevent mutations and aberrations. For
cancer (stem) cells, it provides a highly effective first-line defense
mechanism against DNA-targeting chemotherapeutic agents
currently used in the clinic. Given that HMGA2 is not translated
in normal somatic cells, this HMGA2 fork chaperone function
provides a promising rationale for the development of therapeu-
tic strategies to specifically target cancer (stem) cells.
EXPERIMENTAL PROCEDURES
Cell Lines and Chemicals
Recombinant HT1080-C1 and HT1080-C2 cell lines were generated from indi-
vidual colonies after lentiviral transduction of HT1080 cells with pTRIPz-
shHMGA2 (Origene), followed by puromycin selection. HMGA2-expressing
and mock UTC8505 transfectants were generated as previously described
(Summer et al., 2009). Culture conditions for HUES7 were described previ-
ously (Tan et al., 2007). mESCs J1 were cultured in standard ESC media.
Cancer cell lines were grown in Dulbecco’s modified Eagle’s medium with
10% fetal bovine serum (Invitrogen). HMGA2 was downregulated by induction
of shHMGA2 (GCCAACTCTTCTATTTATGGAT) with 2 mg/ml doxycycline
hyclate (Sigma), which was applied once every day for 4 days.
Antibodies
The primary antibodies used were rabbit polyclonal anti-HMGA2 (1:100;
Abcam), rabbit monoclonal anti-HMGA2 (Cell Signaling), rabbit monoclonalCanti-ATM (1:1,000; Cell Signaling), rabbit polyclonal anti-ATR (1:1,000;
Cell Signaling), mouse monoclonal anti-Phospho-ATM(Ser1981) (1:1,000;
Cell Signaling), rabbit polyclonal anti-Phospho-CHK1(Ser345) (1:1,000; Cell
Signaling), mousemonoclonal anti-PCNA (1:2,000; Cell Signaling), rabbit poly-
clonal anti-PCNA (1:100; Abcam), mouse monoclonal anti-RPA32 (1:100;
Abcam), mouse monoclonal anti-BrdU (1:100, B44; BD) to detect IdU, and
rat monoclonal anti-BrdU (1:100, BU1/75; abcam). The secondary antibodies
were donkey anti-rabbit immunoglobulin G Alexa Fluor 488 (1:200; Invitrogen),
goat polyclonal anti-mouse TRITC (1:100; Abcam), and horseradish peroxi-
dase-conjugate goat anti-rabbit (1:1,000; Santa Cruz).
In Situ PLA
In situ PLA was performed using the Duolink Detection Kit (Olink Bioscience)
with PLA PLUS and MINUS probes for rabbit and mouse based on the manu-
facturer’s protocol. Briefly, HU-nontreated HT1080 cells grown on glass cov-
erslips were labeled with 10 mMEdU for 15 min followed by immediate fixation
and further staining. HU-treated cells were labeled with 10 mM EdU for 15 min
before 5 mM HU was added into the same medium for 16 hr. Cells were
washed once with PBS and fixed in 4% formaldehyde in PBS (pH 7.4) for
10 min. After three washes with PBS buffer, the cells were permeabilized
with either 0.5% Triton in pH 7.4 PBS for 10 min or ice-cold methanol at
20C for 10 min when PCNA antibodies were applied. Cells were washed
with PBS three times before blocking with 5% BSA in PBS with Tween-20
(PBST) buffer for 1 hr. The cells were incubated with different combinations
of primary antibodies (rabbit monoclonal anti-HMGA2 [1:400; Cell Signaling],
mouse monoclonal anti-RPA32 [1:100; Abcam], mouse monoclonal anti-
PCNA [1:100; Cell Signaling], and rabbit polyclonal anti-PCNA [1:100; Abcam])
diluted in PBST with 1% BSA in a 37C water bath for 1 hr. After three washes
with PBST, the cells were incubated with oligonucleotide-conjugated probe
secondary antibodies. The recognition of primary antibodies initiated a DNA-
amplification-based reporter system that generated a signal only when the dis-
tance between two proteins was <40 nm. The labeled EdU was detected with
the use of a Click-iT EdU Imaging Kit (Invitrogen). Cells were counterstained
with DAPI andmounted. Images were obtained with a Zeiss LSM 710 confocal
microscope.
E. coli Cell-Survival Assays
Overnight cultures were inoculated (1:200) into fresh lysogeny broth (LB)
medium with or without isopropyl b-D-1-thiogalactopyranoside and continued
to culture for about 2 hr until OD600 reached 0.3–0.4. For low-pH treatment,
equal numbers of cells were resuspended in 3 ml LB medium (pH 3.25) and
incubated at 37C for 2 hr without shaking. For HU treatment, equal numbers
of cells were resuspended in 2.7 ml fresh LB with or without 300 mM HU and
incubated at 37C for 2 hr at 100 rpm. Equal numbers of cells were plated in
serial dilutions. Assays were performed in triplicate for each serial dilution.
Full details regarding other experimental procedures can be found in Sup-
plemental Experimental Procedures.
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